1 Gonzalez FJ. Human Cytochromes P450:problems and perspects. Tips, 1992, 13:346
2 Rost KL, Roots I. Acceler ated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios:coincidence with plasma clearance and breath test. Clin Pharmacol Ther, 1994, 55:402
3 Kalow W, Tang BK. The use of caffeine for enzyme assays:acritical appraisal. Clin Pharmacol Ther, 1993, 53:503
4 欧阳冬生, 谢红光, 周宏灏.咖啡因在人体C YP 1A 2 酶活 性检测中的作用.湖南医学, 1997, 14(1):40
5 Notarianni LJ, Oliver SE, Dobrocky P, et al. Caffeine as ametabolic probe:a comparison of the metabolic ratios, used to assess CYP1A 2 acivity. Br J Clin Pharmacol, 1995, 39:65
6 赵莉, 楼雅卿.人类细胞色素P450 药物氧化代谢遗传多 态性分子机制的研究现状.生理科学进展, 1997, 28(1):35
7 Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cyto chrome P4501A2 1A2 in man. Br J Clin Pharmacol, 1990, 29:651
8 Brosen K, Skjelbo E, Birgitte B, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Blochem pharmacol, 1993, 45:1211
9 Fuhr U, Wolff T, Harder S, et al. Inhibitory potency of quinolone antibacterial agents in cytochrome P4501A2 activity in vivo and in vitro. Am J Antimicrob Agents Chomother, 1992, 36:942
10 楼雅卿, 匡唐泳, 美芬妥英(mepheny toin)代谢及其羟 化代谢移态性研究.中国临床药理学杂志, 1992, 8(3):173
11 Somogyi AA, Reinhard HA, Bochner F. Pharmacokinetic evaluation of proguanil:a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Br J Clin Pharmaco l, 1996, 41:175
12 Chang M, Tybring G, Dahl ML, et al. Inte rphenotype differences in disposition and effect on gastrin levels of omeprazole:suitability of omeprazole as aprobe for CYP2C19.Br J Clin phamacol, 1995, 39:511
13 Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drugmet abolism in humans. J Clin Pharmacol, 1997, 37:40s
14 Sohm DR, Kwon JT, Kim HK, et al. Metabolic disposition of lansoprazole in relation to the s-mephenytoin 4'-hydr oxylation phenotype status. Clin Pharmacol Ther, 1997, 61:574
15 Kevorkin JP, Michel C, Hofmann U, et al. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure. Comparison of sparteine and dextromethorphan. Clin PHrmacol Ther, 1996, 59:583
16 Dahl ML, Johansson L, Bertilsson L, et al. Ultrarapid hydroxlation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther, 1995, 274:516
17 Bertilsson L, Dahl ML. Polymorphic drug oxidation:relevance to the trentment of psychotic disorders. CNS Drugs, 1996, 5(3):200
18 Frye RF, Mauro K, Adedoyin A, et al. Nonlinear pharm acokinetics of chlorzox azone in humans. Clin Pharmacol Ther, 1995, 57:217
19 Zanger RC, Woodcroft KJ, Novak RF. Differential effects of ciprofibrate on renal and hepatic cytochrome P4502E1 expression. Toxicol Appl Pharmacol, 1996, 141:110
20 Park BK, Kitteringham NR, Pirmohamed M, et al. Relevance of induction of human drug-me tabolizing enzymes:pharmacologic and toxicological implications. Br J Clin Pharmacol, 1996, 41:477
21 Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A4 activity in young healthy men. Clin Pharmacol Ther, 1993, 54:621
22 Lown KS, Kolears JC, Thummel KE, et al. Interpationts hotorogoncity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erthyromycin breath test. Drug Metab Dispos, 1994, 22:947
23 Schuetz EG, Shuetz JD, Grogan WM, et al. Expression of cytochrome P4053A in amphibian, rat, and humankidney. Arch Biochem Biophys, 1992, 294:206 |
